Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Protein That Predicts Tamoxifen Resistance is Identified

05.12.2003


Kimberly Blackwell, M.D.


Researchers at the Duke Comprehensive Cancer Center have identified a protein that breast cancer tumors over-produce when they become resistant to the drug tamoxifen. The researchers said their finding could help them predict which tumors will benefit from tamoxifen -- the front-line drug used to treat operable breast cancer -- and which tumors won’t.

Future studies will be able to determine if tumors that over-produce this protein, called MTA-1, could be treated with a different hormonal therapy following their initial treatment with surgery, chemotherapy and/or radiation, said Kimberly Blackwell, M.D., assistant professor of oncology at the Duke Comprehensive Cancer Center.

Blackwell will present her team’s findings on Dec. 4 at the 26th annual San Antonio Breast Cancer Symposium.



Their latest findings supports last year’s discovery, reported at the same annual meeting, in which Blackwell demonstrated that tamoxifen-resistant tumors actually change their cellular characteristics to become responsive to other types of drugs. Blackwell says that elevated levels of MTA-1 represent one of these cellular changes in tumors that stop responding to tamoxifen.

"MTA-1 is just one of the proteins that plays a role in tamoxifen resistance, but it is one important step toward helping us better target our therapies toward each woman’s particular type of tumor," said Blackwell. "Theoretically, we could biopsy women at the time of diagnosis and select an alternative drug to tamoxifen if their tumors over-express MTA-1."

Furthermore, she said, MTA-1 is known to be a predictor of poor prognosis and the potential for breast cancer metastasis, so that testing for its presence prior to treatment could help them devise more aggressive strategies from the outset.

In years past, tamoxifen was the only option to help prevent breast cancers from recurring in women with estrogen-positive tumors, said Blackwell. But a percentage of women develop resistance to the drug.

To better understand this phenomenon, Blackwell and colleagues developed a strain of mice whose tumors eventually became resistant to tamoxifen. Once tamoxifen resistance was achieved, they conducted a gene array analysis to determine which genes were over-expressed in the new tumor line. They identified 20 different such genes, and found that MTA-1 was a gene that was strongly over-expressed in the tamoxifen-resistant tumors.

To date, scientists have found only a few other genes or proteins over-expressed in tamoxifen-resistant tumors, making the new discovery an important one for determining how a tumor will respond to treatment.

"We have a multitude of hormonally based drugs at our disposal that are designed to treat or prevent breast cancer and its recurrence," said Blackwell. "Our ultimate goal is to test tumors at the time of diagnosis to determine what their molecular signatures are and then to select the best therapy aimed at treating the tumor."

Other authors on the research team, all from Duke, include Mark Dewhirst, Ph.D., Donald McDonnell, Ph.D., Holly Dressman, M.D., Stacey A. Snyder, and Jeffrey R. Marks, Ph.D.

Becky Levine | dukemed news
Further information:
http://dukemednews.org/news/article.php?id=7268

More articles from Health and Medicine:

nachricht PET imaging tracks Zika virus infection, disease progression in mouse model
20.09.2017 | US Army Medical Research Institute of Infectious Diseases

nachricht 'Exciting' discovery on path to develop new type of vaccine to treat global viruses
18.09.2017 | University of Southampton

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

Im Focus: Silencing bacteria

HZI researchers pave the way for new agents that render hospital pathogens mute

Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Molecular Force Sensors

20.09.2017 | Life Sciences

Producing electricity during flight

20.09.2017 | Power and Electrical Engineering

Tiny lasers from a gallery of whispers

20.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>